The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA). UDCA is a medication used in the management and treatment of PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to